Filed revenue acceleration
Active · now 13.42%TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.
SNY Sanofi
Healthcare
40.07
Close 10/9
- Open
- 40.17
- High
- 40.31
- Low
- 39.92
- Prev close
- 40.23
- Volume
- 2.1M
52W 39.18 52.68
Loading candles…
Is Sanofi a buy? Fundamentals and valuation first
As of 2026-10-09
Quality: Good, Growth: Good, Risk / liquidity: Strong.
Quality Good All 3 indicators are Good.
ROE, TTM (%) 5.72 53th percentile Good
Operating margin, TTM (%) 14.8 65th percentile Good
FCF margin, TTM (%) 16.92 72th percentile Good
Growth Good Revenue growth, TTM YoY is Good.
Revenue growth, TTM YoY (%) 13.42 67th percentile Good
Momentum Neutral All 2 indicators are Average.
60-day return (%) -9.36 39th percentile Average
240-day return (%) -18.07 36th percentile Average
Risk / liquidity Strong 20-day dollar volume is Top; 60-day annualized volatility is Good.
20-day dollar volume 127,439,529 89th percentile Top
60-day annualized volatility (%) 20.18 22th percentile Good
Sanofi (SNY) peers and tracking
Watchlist
This page refreshes daily after the close. Add Sanofi to your watchlist to track signal changes on your next visit.
Sanofi (SNY) quant signal backtests
Signals active now
Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.
More history: Market-wide momentum baseline, Signals not active now
Market-wide momentum baseline
Across 98,394 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.23%, a 57.8% positive-return rate, and +2.88 percentage points of average excess return versus the S&P 500.
Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).
Signals not active now
Inactive signals still show the stock-specific historical forward-return distribution for context.
52-week adjusted-price high
PendingAdjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.
14 times historically; 60-day forward avg -5.11%, win rate 21.4%, beating the market by -7.01 pts on average.
Top-quintile 6-month momentum
PendingThe stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.
11 times historically; 60-day forward avg -4.58%, win rate 27.3%, beating the market by -3.29 pts on average.
Continue researching Sanofi with the evidence above.
Continue in Studio ↗Method and limits
- Returns use us_price:adj_close, adjusted for splits and dividends where available.
- Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
- Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
- The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
- Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
- Overlapping event windows are descriptive distributions, not independent samples.
- This is an American depositary receipt (ADR). The data does not say how many ordinary shares each ADR represents, so per-share and market-value metrics (P/E, price/book, free-cash-flow yield, EPS growth and earnings surprises) are not computed.
- ADRs listed on NYSE or NASDAQ are covered as a separate group selected by dollar volume, in addition to the common-stock universe; the 6-month momentum signal ranks each ADR against the liquid US common stocks.
- Financial statements are reported in EUR. Operating margin, ROE and revenue growth are computed within EUR; no figure divides the USD share price by EUR amounts.
This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.